SOOSAN CEBOTICS

As of June 30, 2026, SOOSAN CEBOTICS carries a market capitalization of 114.25B, placing it among publicly traded companies globally. Its enterprise value stands at 131.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SOOSAN CEBOTICS has 62.40M shares outstanding.

As of June 30, 2026, SOOSAN CEBOTICS trades at a trailing price-to-earnings ratio of 6.16. The price-to-sales ratio is 0.47, and the price-to-book ratio stands at 0.54.

As of June 30, 2026, SOOSAN CEBOTICS trades at an EV/EBITDA multiple of 5.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.71 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 131.14B versus a market cap of 114.25B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SOOSAN CEBOTICS maintains a current ratio of 2.65, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.98, indicating elevated leverage, while an interest coverage ratio of 19.28 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SOOSAN CEBOTICS posted a return on equity (ROE) of 9.32, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.77 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.62, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.13, useful for judging operating efficiency across full business cycles. The company generates approximately 664.16M in revenue per employee across its workforce of 368.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.63 indicates how many times SOOSAN CEBOTICS sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SOOSAN CEBOTICS recorded 3.71B in income tax expense. That works out to an effective tax rate of 16.68, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 22.25B, leaving 18.54B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, SOOSAN CEBOTICS's stock has declined approximately 3.57% over the past 52 weeks. The 50-day moving average sits at 1,819.80, while the 200-day moving average is 2,065.26.

Over the twelve months ended June 30, 2026, SOOSAN CEBOTICS generated 244.91B in revenue and converted that into 18.54B in net income, yielding earnings per share of 297.11. EBITDA reached 26.04B, while operating income came in at 19.53B.

As of June 30, 2026, SOOSAN CEBOTICS holds 37.75B in cash and equivalents against 54.63B in total debt, resulting in a net debt position of 30.87B. Total book value stands at 210.32B, with working capital of 109.55B providing operational flexibility.

SOOSAN CEBOTICS produced -7.99B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.25B in capital expenditures, free cash flow totaled -18.24B - equivalent to -292.27 per share.

Over the twelve months ended June 30, 2026, SOOSAN CEBOTICS posted a gross margin of 22.82, reflecting its pricing power and cost economics. The operating margin of 7.98 and net profit margin of 7.57 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, SOOSAN CEBOTICS paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -15.96: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.22, meaning SOOSAN CEBOTICS raised more capital through share issuance and new debt than it returned via dividends and buybacks.

SOOSAN CEBOTICS's most recent stock split took place on July 15, 2004 with a 1:10 split ratio.

As of June 30, 2026, SOOSAN CEBOTICS has an Altman Z-Score of 3.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.